

Giovanni Schinzari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/529070/publications.pdf>

Version: 2024-02-01

23
papers

418
citations

1039406

9
h-index

752256

20
g-index

23
all docs

23
docs citations

23
times ranked

858
citing authors

#	ARTICLE	IF	CITATIONS
1	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 4333.	5.8	82
2	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018, 107, 375-386.	1.2	78
3	Pembrolizumab as first-line treatment for metastatic uveal melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1179-1185.	2.0	60
4	The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 501.	1.8	39
5	Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. <i>Melanoma Research</i> , 2017, 27, 591-595.	0.6	28
6	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in <i>RAS</i> mutant metastatic colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 16887-16898.	0.8	28
7	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018, 18, 198-203.	0.5	18
8	Fist-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) Versus 5-FU/LV (de Gramont Regimen). <i>Anticancer Research</i> , 2017, 37, 5193-5197.	0.5	16
9	The risk of malignancy of atypical urothelial cells of undetermined significance in patients treated with chemohyperthermia or electromotive drug administration. <i>Cancer Cytopathology</i> , 2018, 126, 200-206.	1.4	12
10	DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. <i>Future Oncology</i> , 2019, 15, 2349-2360.	1.1	9
11	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. <i>PLoS ONE</i> , 2015, 10, e0120427.	1.1	9
12	KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 65-74.	1.6	7
13	Methylation study of the Paris system for reporting urinary (TPS) categories. <i>Journal of Clinical Pathology</i> , 2021, 74, 102-105.	1.0	7
14	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. <i>Pathology and Oncology Research</i> , 2019, 25, 513-520.	0.9	5
15	Prognostic Factors Affecting Survival after Pulmonary Resection of Metastatic Renal Cell Carcinoma: A Multicenter Experience. <i>Cancers</i> , 2021, 13, 3258.	1.7	5
16	Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium. <i>Oncotarget</i> , 2018, 9, 8765-8771.	0.8	5
17	Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility. <i>Anticancer Research</i> , 2017, 37, 6453-6458.	0.5	5
18	New biomarkers to predict response to oxaliplatin-based chemotherapy in metastatic colorectal cancer: KRAS and ERCC1.. <i>Journal of Clinical Oncology</i> , 2012, 30, 500-500.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review. Protein and Peptide Letters, 2020, 27, 1276-1287.	0.4	2
20	Supportive simultaneous care: A novel approach to frail cancer patients.. Journal of Clinical Oncology, 2012, 30, e16553-e16553.	0.8	1
21	Resection of lung metastases from colorectal cancer: Analysis of outcome and prognostic factors.. Journal of Clinical Oncology, 2015, 33, e14556-e14556.	0.8	0
22	Potential role of IL-8 and eNOS polymorphisms in the outcome of bevacizumab-treated colorectal cancer patients: an exploratory analysis.. Journal of Clinical Oncology, 2015, 33, e22015-e22015.	0.8	0
23	Psychological status and pain outcome evaluation in patients with painful bone metastases from castration resistant prostate cancer treated with 223Radium.. Journal of Clinical Oncology, 2016, 34, e16512-e16512.	0.8	0